Florida Biologix Signs cGMP Agreement with National Taiwan University Hopsital

Florida Biologix (Alachua, FL), a biopharmaceutical development and contract manufacturing organization, has entered into a current good manufacturing practices (cGMP) manufacturing agreement with the National Taiwan University Hospital (Taipei, Taiwan). Under the agreement, Florida Biologix will produce a Phase 1 clinical batch of a novel therapy for the rare genetic disease, aromatic amino acid decarboxylase (AADC) deficiency.

Florida Biologix release (PDF)